MedTrace Logo

Sphenopalatine Block Versus BOTOX in Management of Chronic Migraine

NCT06974617 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2025-05-16

No results posted yet for this study

Summary

This trial compares the efficacy and safety of sphenopalatine ganglion block (SPGB) and intramuscular BOTOX injection in chronic migraine.

Conditions

  • Sphenopalatine Block
  • BOTOX
  • Chronic Migraine

Interventions

DRUG

Sphenopalatine block

Patients will receive 2 ml of 2% lidocaine using a nasal applicator in each nostril.

DRUG

Botulinum Toxin Type A

Patients will receive Botulinum Toxin Type A 100 units administered in a fixed dose and site paradigm.

Sponsors & Collaborators

  • Cairo University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-15
Primary Completion
2025-10-01
Completion
2025-10-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06974617 on ClinicalTrials.gov